Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mundipharma International Limited

https://www.mundipharma.com

Latest From Mundipharma International Limited

Deal Watch: Adaptimmune, TCR2 Join Forces As Cell Therapy Company Focused On Solid Tumors

All-stock merger will create new company owned 75% by Adaptimmune’s shareholders. Grifols, Selagine to explore antibody approach to treating dry eye disease, and other recent deals.

Deal Watch Business Strategies

Chinese Biotechs Ascend Deal-Making By Partnering Up Claudin 18.2 Agents

The recent partnerships on Claudin 18.2-targeting agents between Chinese biotechs and big pharma have brought China innovation to a new phase that Chinese firms can be proud of, an executive from Keymed Biosciences, one of the Chinese biotechs involved in such deals, tells Scrip in an interview.

China Deals

China’s Kelun Expects ADC Strategy To Deliver By Balancing Safety, Efficacy

After inking recent jumbo licensing deals with Merck & Co., Kelun sheds more light on a partnership that traces back to 2020. The Chinese generics-focused firm also elaborates on the design rationale behind its antibody-drug conjugate programs, including the potential competitive benefits of its asset targeting Claudin 18.2.

China Clinical Trials

Dealmaking Quarterly Statistics, Q4 2022

During Q4, biopharma merger and acquisition value reached $35.7bn and drew in $62.1bn in potential deal value from alliances. Device company M&A values reached $19.2bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $4.8bn.

Deals Market Intelligence
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • OTC, Consumer
    • Drug Delivery
      • Controlled Release
  • Other Names / Subsidiaries
    • Cinfa Biotech GmbH
    • Mundipharma Biologics S.L.
    • Mundipharma EDO GmbH
    • Napp Pharmaceuticals Ltd.
    • Tolmar Australia Pty. Ltd.
UsernamePublicRestriction

Register